tislelizumab + cisplatin + gemcitabine + trilaciclib + FSME-IMMUN

The entity "tislelizumab + cisplatin + gemcitabine + trilaciclib-Pfizer-tick-borne encephalitis" appears to be an erroneous concatenation of two distinct therapeutic categories: a cancer treatment regimen and a viral vaccine. The first part of the name describes a combination of **tislelizumab** (a PD-1 blocking monoclonal antibody), **cisplatin** and **gemcitabine** (cytotoxic chemotherapies), and **trilaciclib** (a CDK4/6 inhibitor used to reduce chemotherapy-induced myelosuppression). This regimen is typically investigated for advanced solid tumors such as small cell lung cancer or urothelial carcinoma. The second part, "Pfizer-tick-borne encephalitis," refers to **FSME-IMMUN** (marketed as TicoVac in the US), an inactivated whole-virus vaccine developed for the prevention of tick-borne encephalitis (TBE). FSME-IMMUN is produced from the Neudörfl strain of the TBE virus and is administered intramuscularly to induce neutralizing antibodies. There is no known clinical use, trial, or biological rationale for a single combination product containing all five of these agents; the name likely resulted from a data processing error where a cancer regimen was appended to a vaccine entry.

Brand names

FSME-IMMUNTicoVacCosela

Other names

Tick-Borne Encephalitis Vaccine (Inactivated)TBE Vaccine